Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1990 Mar 10;300(6725):667–672. doi: 10.1136/bmj.300.6725.667

Lipid lowering drugs.

P O'Connor 1, J Feely 1, J Shepherd 1
PMCID: PMC1662400  PMID: 2182155

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker S. G., Joffe B. I., Mendelsohn D., Seftel H. C. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J. 1982 Jul 3;62(1):7–11. [PubMed] [Google Scholar]
  2. Ball M. J., Mann J. I. Drug treatment for hypercholesterolaemia. Q J Med. 1986 Aug;60(232):733–735. [PubMed] [Google Scholar]
  3. Blane G. F. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med. 1987 Nov 27;83(5B):26–36. doi: 10.1016/0002-9343(87)90868-0. [DOI] [PubMed] [Google Scholar]
  4. Brensike J. F., Levy R. I., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W., Moriarty D. J. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):313–324. doi: 10.1161/01.cir.69.2.313. [DOI] [PubMed] [Google Scholar]
  5. Brown M. S., Goldstein J. L. How LDL receptors influence cholesterol and atherosclerosis. Sci Am. 1984 Nov;251(5):58–66. doi: 10.1038/scientificamerican1184-58. [DOI] [PubMed] [Google Scholar]
  6. Brown W. V., Dujovne C. A., Farquhar J. W., Feldman E. B., Grundy S. M., Knopp R. H., Lasser N. L., Mellies M. J., Palmer R. H., Samuel P. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis. 1986 Nov-Dec;6(6):670–678. doi: 10.1161/01.atv.6.6.670. [DOI] [PubMed] [Google Scholar]
  7. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  8. Chapman M. J. Pharmacology of fenofibrate. Am J Med. 1987 Nov 27;83(5B):21–25. doi: 10.1016/0002-9343(87)90867-9. [DOI] [PubMed] [Google Scholar]
  9. Crepaldi G., Avogaro P., Descovich G. C., Di Perri T., Postiglione A., Sirtori C. R., Strano A., Ventura S., Musatti L. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis. 1988 Mar;70(1-2):115–121. doi: 10.1016/0021-9150(88)90105-0. [DOI] [PubMed] [Google Scholar]
  10. Duffield R. G., Lewis B., Miller N. E., Jamieson C. W., Brunt J. N., Colchester A. C. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet. 1983 Sep 17;2(8351):639–642. doi: 10.1016/s0140-6736(83)92527-8. [DOI] [PubMed] [Google Scholar]
  11. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  12. Goldbourt U., Holtzman E., Neufeld H. N. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J (Clin Res Ed) 1985 Apr 27;290(6477):1239–1243. doi: 10.1136/bmj.290.6477.1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gordon T., Kannel W. B., Castelli W. P., Dawber T. R. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 1981 Aug;141(9):1128–1131. [PubMed] [Google Scholar]
  14. Grundy S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988 Jul 7;319(1):24–33. doi: 10.1056/NEJM198807073190105. [DOI] [PubMed] [Google Scholar]
  15. Havel R. J. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am. 1982 Mar;66(2):441–454. doi: 10.1016/s0025-7125(16)31429-8. [DOI] [PubMed] [Google Scholar]
  16. Hulley S. B., Rhoads G. G. The plasma lipoproteins as risk factors: comparison of electrophoretic and ultracentrifugation results. Metabolism. 1982 Aug;31(8):773–777. doi: 10.1016/0026-0495(82)90074-9. [DOI] [PubMed] [Google Scholar]
  17. Illingworth D. R., Olsen G. D., Cook S. F., Sexton G. J., Wendel H. A., Connor W. E. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial. Atherosclerosis. 1982 Aug;44(2):211–221. doi: 10.1016/0021-9150(82)90115-0. [DOI] [PubMed] [Google Scholar]
  18. Kane J. P., Malloy M. J. Treatment of hypercholesterolemia. Med Clin North Am. 1982 Mar;66(2):537–550. doi: 10.1016/s0025-7125(16)31434-1. [DOI] [PubMed] [Google Scholar]
  19. Kane J. P., Malloy M. J., Tun P., Phillips N. R., Freedman D. D., Williams M. L., Rowe J. S., Havel R. J. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981 Jan 29;304(5):251–258. doi: 10.1056/NEJM198101293040502. [DOI] [PubMed] [Google Scholar]
  20. Kesäniemi Y. A., Grundy S. M. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA. 1984 May 4;251(17):2241–2246. doi: 10.1001/jama.1984.03340410049031. [DOI] [PubMed] [Google Scholar]
  21. Knopp R. H., Brown W. V., Dujovne C. A., Farquhar J. W., Feldman E. B., Goldberg A. C., Grundy S. M., Lasser N. L., Mellies M. J., Palmer R. H. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med. 1987 Nov 27;83(5B):50–59. doi: 10.1016/0002-9343(87)90871-0. [DOI] [PubMed] [Google Scholar]
  22. Monk J. P., Todd P. A. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 1987 Jun;33(6):539–576. doi: 10.2165/00003495-198733060-00002. [DOI] [PubMed] [Google Scholar]
  23. Niort G., Bulgarelli A., Cassader M., Pagano G. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis. 1988 Jun;71(2-3):113–119. doi: 10.1016/0021-9150(88)90135-9. [DOI] [PubMed] [Google Scholar]
  24. Olsson A. G., Orö L. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis. 1982 Apr;42(2-3):229–243. doi: 10.1016/0021-9150(82)90153-8. [DOI] [PubMed] [Google Scholar]
  26. Pocock S. J., Shaper A. G., Phillips A. N., Walker M., Whitehead T. P. High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):515–519. doi: 10.1136/bmj.292.6519.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rouffy J., Chanu B., Bakir R., Djian F., Goy-Loeper J. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis. 1985 Mar;54(3):273–281. doi: 10.1016/0021-9150(85)90121-2. [DOI] [PubMed] [Google Scholar]
  28. Schaefer E. J., Levy R. I. Pathogenesis and management of lipoprotein disorders. N Engl J Med. 1985 May 16;312(20):1300–1310. doi: 10.1056/NEJM198505163122007. [DOI] [PubMed] [Google Scholar]
  29. Shepherd J., Packard C. J., Bicker S., Lawrie T. D., Morgan H. G. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980 May 29;302(22):1219–1222. doi: 10.1056/NEJM198005293022202. [DOI] [PubMed] [Google Scholar]
  30. Tobert J. A. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation. 1987 Sep;76(3):534–538. doi: 10.1161/01.cir.76.3.534. [DOI] [PubMed] [Google Scholar]
  31. Yamamoto A., Matsuzawa Y., Yokoyama S., Funahashi T., Yamamura T., Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986 Jun 27;57(16):29H–35H. doi: 10.1016/0002-9149(86)90434-0. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES